Thank you!

Your quote has been successfully submitted!

For products requiring additional information, our team will contact you within 1 business day

Failed

There was an error submitting your quote. Please try again.

Recombinant Human BRD4 (N-10His-Flag)– MSE Supplies LLC

Free Shipping on MSE PRO Online Orders of $500 or More! U.S. Orders Only * Offer Excludes Hazmat Shipments *

Menu

This product has been added to the cart.

Recombinant Human BRD4 (N-10His-Flag)

SKU: PKSH033982-50

  • £28800
  • Save £3300



Recombinant Human BRD4 (N-10His-Flag)

 

SKU # PKSH033982
Expression Host E.coli

 

 

Description

Synonyms HUNK1, HUNK1bromodomain-containing protein 4, HUNKI, MCAP
Species Human
Expression Host E.coli
Sequence Glu49-Glu460
Accession O60885
Calculated Molecular Weight 49.0 kDa
Observed Molecular Weight 55-60 kDa
Tag N-His-Flag
Bio-activity Not validated for activity
  

 

Properties

Purity > 90 % as determined by reducing SDS-PAGE.
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method.
Storage Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.
Shipping This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at < - 20°C.
Formulation Supplied as a 0.2 μm filtered solution of 50mM HEPES, 200mM NaCl, 1mM DTT, 10% Glycerol, pH 7.5.
Reconstitution Not Applicable



Background

Bromodomain-containing protein 4 (BRD4) is a member of the BET class chromatin reader proteins that bind acetylated histones and play a key role in transcriptional regulation and transmission of epigenetic memory. Remains associated with acetylated chromatin throughout the entire cell cycle and provides epigenetic memory for postmitotic G1 gene transcription by preserving acetylated chromatin status and maintaining high-order chromatin structure. BRD bromodomains serve as recognition motifs for acetylated lysine residues on histones, while the NET domain may function by promoting phosphorylation of the C-terminal domain (CTD) of RNA Polymerase II. Some specific inhibitors of BRD4 that prevent binding to acetylated histones by binding Asn-140 and Asn-433 are promising therapeutic molecules for the treatment of leukemias. BRD4 is a potential therapeutic target in many diseases including breast cancer, AML, multiple myeloma, colon cancer and others.